Weight Loss
2 articles

Computational Science & Software
Boehringer's obesity drug shows efficacy, faces tolerability challenge
In a pivotal Phase 3 obesity trial, 19% of patients on Boehringer Ingelheim and Zealand Pharma's experimental drug survodutide discontinued treatment due to severe gastrointestinal side effects, a rat
Yasmin Haddad·June 8, 2026

Cosmos & Physics
Pfizer advances monthly obesity drug targeting triple hormone receptors
Pfizer is advancing a monthly weight-loss injection, danuglipron, having announced positive early-stage data.
Dr. Evelyn Reed·June 7, 2026